Supportive Oncodermatology in Pediatric Patients

center dot Targeted cancer therapies block specific molecular pathways involved in the growth, progression, and spread of cancer.center dot Pediatric dermatology literature is emerging on the specific types and prevalence of cutaneous reactions to targeted therapies that hone in on membrane-bound receptors (eg, BCR-ABL, EGFR, or SMO inhibitors), intracellular signaling targets (eg, BRAF, MEK, mTOR), and antiangiogenesis agents (eg, VEGF), as well as targeted immunotherapies.center dot Data regarding the timing, severity, and treatment algorithm for these cutaneous reactions are most plentiful for BRAF, MEK, and EGFR inhibitors.center dot Further research on the most common cutaneous reactions of targeted therapy in children, treatments, and prevention is crucial to better serve the needs of this population.